ARDX stock forecast, quote, news & analysis
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs... Show more
Why Ardelyx (ARDX) Stock Is Down -11.9% in the Last 30 Days
Key Takeaways
- Ardelyx shares declined roughly 11.9% over the last 30 days, falling from about $3.27 on October 8 to $2.88 at the November 6 close.
- The pullback extends a downtrend that began in early August, when the company cut its full-year IBSRELA guidance and withdrew long-term XPHOZAH guidance.
- Third-quarter 2026 results showed resilience, with total product revenue up 19% year over year and a net loss narrowed to $700,000.
- Management reaffirmed 2026 revenue guidance and reiterated its expectation of reaching profitability in 2027.
- Securities class-action filings and continued payer and reimbursement concerns have weighed on investor sentiment.
- Explore detailed Price Targets, Earnings, and Forecast data for ARDX to understand analyst expectations.
- Discover Trending AI Robots to see which AI-driven trading strategies are currently active across the market.
Ardelyx (ARDX) Company Overview and Market Position
Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for significant unmet medical needs. The company has two FDA-approved products in the United States, both based on its tenapanor molecule: IBSRELA, which treats irritable bowel syndrome with constipation (IBS-C) in adults, and XPHOZAH, which reduces serum phosphorus in adults with chronic kidney disease on dialysis.
Ardelyx's pipeline includes a Phase 3 trial of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor. Investors follow the stock for its commercial revenue growth, its path toward profitability, and the regulatory and reimbursement dynamics affecting XPHOZAH.
Ardelyx (ARDX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Ardelyx shares moved from a closing price of $3.27 on October 8 to $2.88 on November 6, a decline of approximately 11.9%. The move was not a single sharp event but rather a steady grind lower punctuated by a brief bounce in early November following third-quarter earnings before the stock faded again.
The quarterly picture is steeper. In early August, ARDX traded near $4.87 before falling about 18% in a single session to $4.00 on August 7 after a guidance reset. From that early-August level of roughly $4.87 to the November 6 close of $2.88, the stock has declined approximately 41%, reflecting a sustained repricing rather than a short-term correction.
What Drove ARDX Stock Price in the Last 30 Days
Multiple securities class-action lawsuits filed against Ardelyx kept litigation headlines in focus throughout October. The complaints allege that the company made misleading statements about payer-related access barriers for IBSRELA and XPHOZAH, and several firms set a lead-plaintiff deadline of November 16, 2026. These recurring filings contributed to persistent selling pressure.
Third-quarter 2026 results, reported in early November, showed underlying commercial strength: total product revenue of $125.5 million, up 19% year over year, with IBSRELA revenue rising 23% to $96.3 million and XPHOZAH revenue up 7% to $29.2 million. The net loss narrowed to $700,000, and the company ended the quarter with $285.3 million in cash and short-term investments. Ardelyx reaffirmed its full-year 2026 guidance for both products and reiterated that it expects profitability in 2027. Despite the positive fundamentals, shares faded after an initial pop, suggesting broader concerns continued to dominate sentiment.
What Drove ARDX Stock Performance Over the Last Quarter
The quarterly decline traces back to August 6, 2026, when Ardelyx reduced its full-year 2026 IBSRELA revenue guidance and withdrew its long-term XPHOZAH revenue guidance, citing significantly increased payer utilization-management processes that restricted patient access and slowed new-patient starts. Shares fell roughly 18% the following session.
The repricing was compounded by regulatory developments. In June 2026, the U.S. Court of Appeals for the D.C. Circuit affirmed the dismissal of Ardelyx's lawsuit challenging the Centers for Medicare & Medicaid Services' classification of XPHOZAH as a renal dialysis service, clearing the way for the drug to move into Medicare's bundled payment system rather than separate Part D reimbursement. This outcome weakened XPHOZAH's pricing outlook and added uncertainty about long-term revenue growth, keeping the stock under pressure through the fall.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots. Tickeron offers hundreds of automated trading bots that collectively monitor thousands of tickers, but only the top-performing and most relevant bots are highlighted in this section. These bots vary in trading strategy, timeframe, and performance metrics, allowing users to compare approaches and identify strategies aligned with their own objectives. The section provides a neutral, data-driven view of currently active AI trading activity across the market. Exploring the page can help investors see which automated strategies are drawing attention.
ARDX Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor IBSRELA prescription trends and the impact of payer utilization-management requirements, which remain central to Ardelyx's revenue trajectory. The Phase 3 ACCEL trial of IBSRELA in chronic idiopathic constipation is a key pipeline catalyst, with a topline readout expected to provide insight into a potential label expansion. XPHOZAH's performance under Medicare's bundled payment system will also be closely watched, as will any further developments in the securities litigation and the November 16, 2026 lead-plaintiff deadline. Upcoming quarterly results, guidance updates, and operating-expense discipline toward the company's 2027 profitability target round out the key factors to follow.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for ARDX turns positive, indicating new upward trend
ARDX saw its Momentum Indicator move above the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In 69 of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARDX's RSI Indicator exited the oversold zone, 25 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 60 cases where ARDX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
Following a +6.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARDX advanced for three days, in 221 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
ARDX broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARDX entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. ARDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 79 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.990) is normal, around the industry mean (3.498). P/E Ratio (-12.522) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (50.260) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.846) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutic drugs that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases
Industry Biotechnology